CDC Panel Recommends Resuming Johnson & Johnson Vaccine Distribution

A Centers for Disease Control and Prevention advisory panel on Friday recommended the U.S. resume using the Johnson and Johnson Covid-19 vaccine, saying the benefits outweighed the risk.

Members of the panel didn’t recommend U.S. regulators restrict the use of the vaccine based on age or gender, but they did propose that the FDA consider adding a warning label for women under the age 50.

The recommendation, which was adopted 10-4 with one abstention, by the CDC’s Advisory Committee on Immunization Practices, will pave the way for U.S. regulators to...

Vaccine advisers to the US Centers for Disease Control and Prevention voted Friday to recommend resuming use of the vaccine.

An updated warning will be added to the label.
The CDC and US Food and Drug Administration recommended pausing the use of the vaccine on April 13 while they investigated the risk of rare, severe blood clots. On Friday, members of the CDC's Advisory Committee for Immunization Practices agreed the benefits of the vaccine outweigh the risks from rare blood clots linked with the vaccine.